United States · Venture startup

Who invested in ICHOR Vascular

One round we have observed, with the one investor named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Healthcare

Funding summaryUpdated 26 Oct 2026

$2.9Mraised across 1 round since 2024, from 1 source

Latest round
Venture, $2.9MFeb 2024
Investors
1
See who backed them

The rounds

  1. Feb 2024
    Venture$2.9M

    Source recordedSEC filing: $2.9M sold, first sale Jan 2024

Everyone who backed them

IrishAngelsAngel network1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 6 firms list ICHOR Vascular as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.

Queen City AngelsAngel networkPer its own site
Gopher AngelsAngel networkPer its own site
VisionTech PartnersAngel networkPer its own site
Angel Star VenturesAngel networkPer its own site
ExponionVC firmPer its own site
Queen City Angels First FundsVC firmPer its own site

Quick answers about ICHOR Vascular

Who invested in ICHOR Vascular?

ICHOR Vascular's investors include IrishAngels.

How much has ICHOR Vascular raised?

ICHOR Vascular has raised $2.9M across 1 round since 2024.

When did ICHOR Vascular last raise?

ICHOR Vascular's most recent round was a Venture of $2.9M in Feb 2024.

What was ICHOR Vascular's biggest round?

Its most recent round, $2.9M in Feb 2024, is also its largest on record.

Who backed ICHOR Vascular first?

ICHOR Vascular's first round on record, in Feb 2024, was backed by IrishAngels.

What stage is ICHOR Vascular at?

ICHOR Vascular's latest named round is a Venture, in Feb 2024.

Where is ICHOR Vascular based?

ICHOR Vascular is based in the United States.

Companies like ICHOR Vascular

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.